Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,173.91
(
0.12%
)
US TECH 100
26,487.20
(
-0.31%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
104.34
(
2.18%
)
Bitcoin
76,827.02
(
-0.70%
)
News Focus
News Focus
Post# of 257454
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122891
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 221320

Thursday, 06/20/2019 10:13:05 AM

Thursday, June 20, 2019 10:13:05 AM

Post# of 257454
ABUS starts phase-1 trial of AB-729 for HBV:

https://www.globenewswire.com/news-release/2019/06/20/1871749/0/en/Arbutus-receives-regulatory-clearance-to-initiate-Phase-1a-1b-Clinical-Trial-of-AB-729.html

AB-729 is an RNAi-based HBV-replication inhibitor; it should not be confused with AB-506, ABUS’ HBV “core” inhibitor that is already in phase-1 and will have an initial data readout this summer.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today